Coeptis Therapeutics Inc (COEP) Stock
COEP is no longer traded. Coeptis Therapeutics was delisted from the Nasdaq in April 2026.
Prices on this page are historical; the last trade was April 24, 2026 at $16.40.
Coeptis Therapeutics stock price history
COEP final trading statistics
- Final close
- $16.40
- Final trading day
- Apr 24, 2026
- Market cap at delisting
- $102.06M
- Shares outstanding
- 6.22M
- Final 52-week range
- $6.26 – $21.41
- Avg. volume (final 3 mo.)
- 51,489
- All-time high (split-adj.)
- $130.00 · Oct 2022
- All-time low (split-adj.)
- $0.00 · Oct 2022
- Return since IPO
- +1366566.7%
- Beta
- -0.43
- Book value / share
- $2.36
- Price / book
- 6.95
Coeptis Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $1.36M | -$11.9M | — |
| FY2024 | $0.00 | -$10.7M | -$4.29 |
| FY2023 | $0.00 | -$21.3M | -$14.75 |
| FY2022 | $0.00 | -$37.6M | -$2.81 |
| FY2021 | $75.0K | -$13.4M | $1.80 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Coeptis Therapeutics Inc
As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Coeptis Therapeutics stock FAQ
What happened to Coeptis Therapeutics stock?
Coeptis Therapeutics stock was delisted from the Nasdaq. Its final close was $16.40 on April 24, 2026.
Is COEP stock still trading?
No. COEP was delisted from the Nasdaq in April 2026 and no longer trades on a U.S. exchange.
What was the last price of COEP stock?
COEP closed at $16.40 on its final trading day, April 24, 2026, for a market value of about $102.06M.
What were Coeptis Therapeutics's revenue and earnings in its last full fiscal year?
Coeptis Therapeutics reported revenue of $1.36M and net income of -$11.9M in fiscal 2025, its last full year as a public company.
When did Coeptis Therapeutics go public?
Coeptis Therapeutics Inc stock began trading on December 17, 2020.